Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

radium Ra 223 dichloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Bone Metastatic Castration-resistant Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT04521361 2025-09-19

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Bayer

Phase 1 Completed
46 enrolled
Genitourinary

Bone Metastatic Castration-resistant Prostate Cancer

NCT04587427 2024-03-08

DIRECT

Bayer

Completed
1,067 enrolled
Genitourinary

Bone Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡